Head and Neck Cancer, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck
Conditions
Brief summary
The goal of this clinical trial is to determine the best safe dose of xevinapant that can be given in combination with chemotherapy and radiation in patients with head and neck cancer. Up to 4 doses of xevinapant will be tested in the dose escalation portion of the study. After the best safe dose is found during escalation, an additional group of participants will be enrolled at that dose to learn more about the treatment combination (dose expansion). The main question\[s\] it aims to answer are: * what is the maximum safe dose that can be given * what dose should be used in subsequent (phase 2) trials Participants will receive xevinapant in combination with paclitaxel and carboplatin chemotherapy and radiation. Treatment will be given in 3-week cycles for 3 cycles.
Interventions
DRUGXevinapant
Given orally during study treatment on days 1-14 of a 21-day treatment cycles. It will be given continuously during treatment with carboplatin, paclitaxel, and radiation (chemoRT). After completely of the chemoRT dosing, an additional 3 cycles of Xevinapant along will be given.
DRUGCarboplatin
Given with radiation weekly for 7 doses.
DRUGPaclitaxel
Given with radiation weekly for 7 doses.
RADIATIONRadiation Therapy
Radiation will be given together with paclitaxel and carboplatin for 7 weeks.
Sponsors
University of Chicago
EMD Serono
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Pathologically proven diagnosis of squamous cell carcinoma of the head and neck (HNSCC) of the oral cavity, oropharynx, larynx, hypopharynx, nasopharynx, or sinuses. * Patients with oropharynx cancer need p16 determination by immunohistochemistry (where positive is defined as greater than 70% strong nuclear or nuclear and cytoplasmic staining of tumor cells). * Oral cavity, larynx, hypopharynx, or p16-negative oropharynx cancer must be stages T1-2N1-3 or T3-4N0-3 (AJCC 8th edition). Sinus primary must be T4bN0-3 not amenable to surgical resection. * P16-positive oropharynx cancer patients, stages T1-2N1-3 or T3-4N0-3 (AJCC 8th edition staging). 2. The patient has unresected, measurable disease as defined by the presence of at least one measurable lesion per RECIST 1.1. 3. Age \>= 18 years of age 4. Patients must have a contraindication to cisplatin 5. Performance Status of 0-2 6. Adequate hematologic function * White Blood Cell Count (WBC) \>= 2000 cells/mm3 * Absolute neutrophil count (ANC) \>= 1,500 cells/mm3 * Platelets \>= 100,000 cells/mm3 * Hemoglobin \>= 9.0 g/dL 7. Adequate renal function was defined as follows: Creatinine clearance (CrCl) \> 30 mL/min 8. Adequate hepatic function * Total bilirubin \<= 1.5 x upper limit of normal (ULN) (except patients with Gilbert Syndrome who can have total bilirubin \< 3.0 mg/dL) * aspartate aminotransferase (AST) and alanine transaminase (ALT) \<= 2.5 x upper limit of normal (ULN) 9. For women of childbearing potential (e.g. uterus present and menstruating), a negative serum pregnancy test within 14 days prior to registration. 10. Willingness to agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from time of joining the study until 6 months after completing chemotherapy treatment or 3 months after last dose of xevinapant, whichever is the latest. 11. Patients with a history of hepatitis B or C infection are eligible if they have an undetectable viral load. 12. Ability to understand and the willingness to sign a written informed consent document. 13. Availability of tumor tissue for research analysis. Patients who do not have adequate tissue available will need to undergo a new biopsy prior to enrollment on study.
Exclusion criteria
1. Definitive clinical or radiologic evidence of distant (beyond cervical lymph node and neck tissue) metastatic disease. 2. Carcinoma of the neck of unknown primary site of origin 3. Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable if not within \< 3 years 4. Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields; 5. Severe, active co-morbidity defined as follows: * History of bone marrow transplant and organ transplant, including allogeneic stem cell transplantation. * Unstable angina requiring hospitalization in the last 6 months. * New York Heart Association Functional Classification III/IV. * Myocardial infarction within the last 6 months. * Persistent Grade 3-4 electrolyte abnormalities that cannot be reversed despite as indicated by repeat testing. * Ongoing active infection associated with symptoms and/or requires antibiotic therapy at the time of initiation of treatment. 6. Pregnancy and nursing females, if applicable. 7. Receipt of live vaccinations within 28 days prior to study start. 8. Patients who are receiving any other investigational agents. 9. Patients with a "currently active" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for ≥ 3 years. 10. History of allergic reactions attributed to compounds of similar chemical or biologic composition to xevinapant, carboplatin, or paclitaxel. 11. Patients taking prohibited medications and those requiring close monitoring.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determine best safe dose of xevinapant when given in combination with radiation and chemotherapy | 21 days |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival | 5 years | Time from registration to the date of first documented disease progression based on RECIST v1.1, clinical progression, or death due to any cause, whichever occurs first. |
| Number of side effects seen when xevinapant is given in combination with radiation and chemotherapy | 21 days | — |
| Overall Survival | 5 years | Time between the date of registration and the date of death. |
| Locoregional failure | 5 years | Time from registration to the date of first documented disease progression based on RECIST v1.1 in the head and neck. |
| Distant Failure | 5 years | Time from registration to the date of first documented disease progression based on RECIST v1.1 below the clavicles. |
| Response Rate | 5 years | Complete or partial response per RECIST v1.1 criteria |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORAri Rosenberg, ND
University of Chicago
Outcome results
None listed